ELOX Eloxx Pharmaceuticals, Inc. - Common Stock
$17,39
Preço · Ago 19, 2026
Fundamentais a partir de Ago 11, 2026
Intervalo 52 Semanas
$8–$20
78% of range
Classificação do Analista
BUY
7 analysts
Preço-Alvo
$42
+139% upside
P/E (TTM)
—
ROE
30.1%
Margem de Lucro Líquido
—
ELOX Instantâneo da Ação Preço, capitalização de mercado, P/E, EPS, ROE, dívida/patrimônio, intervalo de 52 semanas
Preço
$17.39
Capitalização de Mercado
—
P/E (TTM)
—
EPS (TTM)
$-0.49
Receita (TTM)
$0
Rendimento div.
—
ROE
30.1%
Dívida/Capital
-0.1
Intervalo 52 Semanas
$8 – $20
ELOX Gráfico de Preço da Ação OHLCV diário com indicadores técnicos — panorâmica, zoom e personalize sua visualização
Configure
Desempenho de 10 Anos Tendências de receita, lucro líquido, margens e EPS
Receita e Lucro Líquido
$0
2023-12-31
→
2025-12-31
EPS
$-0.49
2021-12-31
→
2025-12-31
Fluxo de caixa livre
—
2017-06-30
→
2022-12-31
Margens
—
Avaliação Rácios P/E, P/S, P/B, EV/EBITDA — a ação está cara ou barata?
Métrica
Tendência de 5 anos
ELOX
Mediana de Pares
Lucratividade Margens bruta, operacional e líquida; ROE, ROA, ROIC
Métrica
Tendência de 5 anos
ELOX
Mediana de Pares
ROA
-145.4%
—
ROE
30.1%
—
ROIC
59.0%
—
Saúde financeira Dívida, liquidez, solvência — força do balanço patrimonial
Métrica
Tendência de 5 anos
ELOX
Mediana de Pares
Debt / Equity (Dívida / Patrimônio Líquido)
-0.1
—
Current Ratio (Índice de liquidez corrente)
0.3
—
Quick Ratio (Índice de Liquidez Seca)
0.3
—
Crescimento Crescimento da receita, EPS e lucro líquido: YoY, CAGR 3 anos, CAGR 5 anos
Métrica
Tendência de 5 anos
ELOX
Mediana de Pares
Eficiência de Capital Giro de ativos, giro de estoques, giro de contas a receber
Métrica
Tendência de 5 anos
ELOX
Mediana de Pares
ELOX Consenso dos analistas Opiniões de analistas otimistas e pessimistas, preço-alvo de 12 meses, potencial de alta
COMPRA
7 analistas
- Compra forte 2 28,6%
- Compra 4 57,1%
- Manter 1 14,3%
- Venda 0 0,0%
- Venda forte 0 0,0%
Preço-alvo de 12 meses
2 analistas · 2026-08-17
Mediana
$41.50
← Abaixo de todos os alvos
$17.39
Mín
$40.00
Máx
$43.00
Alvo mediano
$41.50
+138,6%
Alvo médio
$41.50
+138,6%
Histórico de Lucros EPS real vs. estimativa, surpresa %, taxa de acerto, próxima data de resultados
Surpresa Média
0.33%
| Período | EPS Actual | EPS est. | Surpresa |
|---|---|---|---|
| 30 de Setembro de 2023 | $-14.41 | $-22.10 | 7.7% |
| 30 de Junho de 2023 | $-21.56 | $-17.28 | -4.3% |
| 31 de Março de 2023 | $-31.68 | $-28.61 | -3.1% |
| 31 de Dezembro de 2022 | $-32.12 | $-33.32 | 1.2% |
| 31 de Março de 2022 | $-2.92 | $-3.03 | 0.11% |
Comparação de pares (subindústria GICS) Métricas chave vs pares do setor
| Ticker | Capitalização de Mercado | P/E | Receita YoY | Margem Líquida | ROE | Margem Bruta |
|---|---|---|---|---|---|---|
| ELOX | — | — | — | — | 30.1% | — |
| CGTX | $120M | -4.2 | — | — | -113.7% | — |
| VRCA | $143M | -4.9 | 370.2% | -50.3% | -492.8% | — |
| TELO | $46M | -4.0 | — | — | -325.7% | — |
| LONA | $71M | -0.3 | — | — | -353.4% | — |
| CING | — | — | — | — | — | — |
| PLRX | $75M | -0.5 | -83.7% | — | -74.4% | — |
| IMA | — | -0.7 | -77.1% | -5668.6% | 192.1% | — |
| TLPH | $56M | — | — | -51035.7% | -120.8% | — |
| BSEM | — | — | — | — | — | — |
Fundamentos Completos Todas as métricas por ano — demonstração de resultados, balanço patrimonial, fluxo de caixa
Demonstração de Resultados 14
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $6M | $0 | · | · | · | · | · | · | · | |
| R&D Expense | · | · | · | · | · | $15M | $26M | $20M | $16M | $9M | |
| SG&A Expense | $3M | $5M | $9M | $11M | $20M | $15M | $24M | $26M | $3M | $854.0K | |
| Operating Expenses | $6M | $9M | $17M | $34M | $66M | $33M | $51M | $48M | $20M | $10M | |
| Operating Income | $-6M | $-2M | $-17M | $-34M | $-66M | $-33M | $-51M | $-48M | $-20M | $-10M | |
| Other Non-op | $443.0K | $-675.0K | $234.0K | $-2M | $-709.0K | $-1M | $-319.0K | $502.0K | $-824.0K | $-7.0K | |
| Pretax Income | $-6M | $-3M | $-17M | $-36M | $-67M | $-35M | $-51M | $-47M | $-21M | $-10M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $122.0K | · | · | |
| Net Income | $-6M | $-3M | $-17M | $-36M | $-67M | $-35M | $-51M | $-47M | $-21M | $-10M | |
| EPS (Basic) | $-0.49 | $-0.84 | $-6.63 | $-16.65 | $-38.15 | · | · | · | · | · | |
| EPS (Diluted) | $-0.49 | $-0.84 | $-6.63 | $-16.65 | $-38.15 | · | · | · | · | · | |
| Shares (Basic) | 12,347,495 | 3,758,804 | 2,570,620 | 2,166,311 | 1,749,071 | · | · | · | · | · | |
| Shares (Diluted) | 12,347,495 | 3,758,804 | 2,570,620 | 2,166,311 | 1,749,071 | · | · | · | · | · | |
| EBITDA | $-6M | · | · | $-34M | $-66M | $-33M | $-51M | $-48M | · | · |
Balanço Patrimonial 22
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5M | $111.0K | $1M | $19M | $42M | $25M | $22M | $49M | $24M | $2M | |
| Prepaid Expense | $479.0K | $142.0K | $194.0K | $661.0K | $913.0K | $1M | $1M | $2M | $355.0K | $837.0K | |
| Current Assets | $5M | $3M | $2M | $20M | $43M | $26M | $58M | $50M | $25M | $3M | |
| PP&E (Net) | $0 | $0 | $35.0K | $169.0K | $216.0K | $133.0K | $201.0K | $248.0K | $278.0K | $41.0K | |
| PP&E (Gross) | $0 | $0 | $313.0K | $349.0K | $387.0K | $446.0K | $488.0K | $452.0K | $332.0K | $56.0K | |
| Accum. Depreciation | $0 | $0 | $278.0K | $180.0K | $171.0K | $313.0K | $287.0K | $204.0K | $54.0K | $15.0K | |
| Other Non-current Assets | · | · | · | · | · | $30.0K | $113.0K | $129.0K | · | · | |
| Total Assets | $5M | $3M | $2M | $21M | $45M | $26M | $59M | $51M | $25M | $3M | |
| Accounts Payable | $3M | $5M | $6M | $3M | $1M | $481.0K | $2M | $747.0K | $2M | $2M | |
| Accrued Liabilities | $2M | $1M | $1M | $3M | $4M | $3M | $5M | $7M | $2M | $619.0K | |
| Current Liabilities | $17M | $27M | $23M | $23M | $10M | $10M | $12M | $8M | $3M | $3M | |
| Capital Leases | $0 | $0 | $2.0K | $135.0K | $804.0K | $33.0K | $425.0K | · | · | · | |
| Total Liabilities | $17M | $27M | $24M | $32M | $23M | $16M | $23M | $8M | · | · | |
| Long-term Debt | $1M | $7M | $4M | $12M | $11M | $11M | $14M | · | · | · | |
| Total Debt | $1M | · | · | $13M | $12M | $12M | $15M | · | · | · | |
| Common Stock | $4.0K | $35.0K | $31.0K | $22.0K | $22.0K | $404.0K | $402.0K | $360.0K | $274.0K | $42.0K | |
| Retained Earnings | $-301M | $-295M | $-291M | $-274M | $-238M | $-172M | $-137M | $-86M | $-39M | $-18M | |
| Treasury Stock | · | · | · | $0 | $2M | $2M | $2M | $1M | · | · | |
| AOCI | · | · | · | · | · | · | $18.0K | · | · | · | |
| Stockholders' Equity | $-12M | $-24M | $-23M | $-11M | $22M | $10M | $36M | $43M | $21M | $610.0K | |
| Liabilities + Equity | $5M | $3M | $2M | $21M | $45M | $26M | $59M | $51M | $25M | $3M | |
| Shares Outstanding | 435,432 | 321,252 | 3,143,390 | 2,166,356 | 2,166,248 | 1,003,930 | 40,030,763 | 35,860,114 | 27,527,738 | 4,205,278 |
Fluxo de Caixa 15
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $235.0K | $541.0K | $2M | $3M | $9M | $9M | $11M | $13M | $101.0K | $78.0K | |
| Deferred Tax | · | · | · | · | · | · | · | · | $10M | · | |
| Restructuring | · | · | · | · | · | $2M | · | · | · | · | |
| Operating Cash Flow | $-6M | $-5M | $-14M | $-32M | $-35M | $-28M | $-39M | $-31M | $-16M | $-9M | |
| CapEx | · | · | · | $66.0K | $89.0K | · | $40.0K | $235.0K | $237.0K | $36.0K | |
| Investing Cash Flow | $1.0K | $38.0K | $309.0K | $-66.0K | $2M | $34M | $-34M | $-317.0K | $-114.0K | $-36.0K | |
| Debt Issued | $3M | $4M | $0 | $0 | $12M | $797.0K | $15M | · | · | · | |
| Net Debt Issued | $3M | · | · | $0 | $12M | $797.0K | $15M | · | · | · | |
| Stock Issued | $0 | $0 | $3M | $0 | $48M | · | $710.0K | $2M | $17M | · | |
| Net Stock Activity | $0 | · | · | $0 | · | · | · | · | · | · | |
| Dividends Paid | · | · | · | · | · | · | $0 | $0 | $0 | · | |
| Financing Cash Flow | $11M | $3M | $-4M | $9M | $51M | $-3M | $47M | $56M | $38M | $10M | |
| Net Change in Cash | $5M | $-1M | $-18M | $-23M | $18M | $2M | $-26M | $24M | $22M | $856.0K | |
| Taxes Paid | · | · | · | · | · | $5.0K | $36.0K | · | · | · | |
| Free Cash Flow | · | · | · | $-32M | $-35M | · | $-39M | $-32M | · | · |
Lucratividade 3
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -145.4% | · | · | -108.9% | -186.3% | -81.0% | -92.8% | -125.0% | · | · | |
| ROE | 30.1% | · | · | 461.1% | -241.0% | -273.2% | -124.9% | -100.0% | · | · | |
| ROIC | 59.0% | · | · | -1833.7% | -192.0% | -153.2% | -99.0% | -111.1% | · | · |
Liquidez e Solvência 4
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.3 | · | · | 0.9 | 4.4 | 2.6 | 4.9 | 6.4 | · | · | |
| Quick Ratio | 0.3 | · | · | 0.8 | 4.2 | 2.5 | 1.9 | 6.2 | · | · | |
| Debt / Equity | -0.1 | · | · | -1.2 | 0.5 | 1.1 | 0.4 | · | · | · | |
| LT Debt / Equity | 0.0 | · | · | -0.8 | 0.5 | 0.6 | 0.3 | · | · | · |
Eficiência 1
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | · | · | · | · | · | · | · | · | · |
Avaliação (TTM) 4
| Métrica | Tendência | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $0 | · | · | · | · | · | · | · | · | · | |
| Net Income TTM | $-6M | · | · | $-36M | $-67M | $-35M | $-51M | $-47M | $-21M | · | |
| Payout Ratio | · | · | · | · | · | · | 0.00% | 0.00% | · | · | |
| Annual Payout | · | · | · | · | · | · | $0 | $0 | $0 | · |
Demonstração de Resultados 11
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q4 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $4M | |
| SG&A Expense | $2M | $2M | · | · | $3M | $2M | $2M | $2M | $3M | $2M | $3M | $3M | $4M | $5M | $7M | $4M | |
| Operating Expenses | $4M | $4M | · | · | $4M | $4M | $4M | $5M | $6M | $7M | $10M | $11M | $12M | $10M | $36M | $8M | |
| Operating Income | $-4M | $-4M | · | · | $-4M | $-4M | $-4M | $-5M | $-6M | $-7M | $-10M | $-11M | $-12M | $-10M | $-36M | $-8M | |
| Other Non-op | $-52.0K | $41.0K | · | · | $1M | $45.0K | $-201.0K | $-747.0K | $-291.0K | $-366.0K | $-322.0K | $-667.0K | $-460.0K | $360.0K | $-329.0K | $-280.0K | |
| Net Income | $-5M | $-4M | · | · | $-3M | $-4M | $-4M | $-6M | $-6M | $-8M | $-11M | $-12M | $-12M | $-10M | $-36M | $-9M | |
| EPS (Basic) | $-0.66 | $-0.08 | · | · | $-0.48 | $-1.31 | $-1.96 | $-2.88 | $-2.92 | $-3.47 | $-4.90 | $-5.36 | $-37.30 | $-0.11 | $-0.54 | · | |
| EPS (Diluted) | $-0.66 | $-0.08 | · | · | $-0.48 | $-1.31 | $-1.96 | $-2.88 | $-2.92 | $-3.47 | $-4.90 | $-5.36 | $-37.30 | $-0.11 | $-0.54 | · | |
| Shares (Basic) | 6,789,165 | 48,210,071 | · | · | -4,555,787 | 2,747,687 | 2,212,364 | 2,166,356 | -4,332,720 | 2,166,404 | 2,166,352 | 2,166,275 | -62,679,116 | 86,208,754 | 66,389,865 | · | |
| Shares (Diluted) | 6,789,165 | 48,210,071 | · | · | -4,555,787 | 2,747,687 | 2,212,364 | 2,166,356 | -4,332,720 | 2,166,404 | 2,166,352 | 2,166,275 | -62,679,116 | 86,208,754 | 66,389,865 | · | |
| EBITDA | $-4M | $-4M | · | · | · | $-4M | $-4M | $-5M | · | $-7M | $-10M | $-11M | · | $-10M | $-36M | $-8M |
Balanço Patrimonial 20
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q4 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $62M | $6M | $5M | $111.0K | $1M | $5M | $4M | $5M | $19M | $25M | $30M | $40M | $42M | $52M | $57M | $18M | |
| Prepaid Expense | $1M | $2M | $479.0K | $142.0K | $194.0K | $635.0K | $841.0K | $1M | $661.0K | $854.0K | $1M | $2M | $913.0K | $864.0K | $2M | $2M | |
| Current Assets | $63M | $9M | $5M | $3M | $2M | $6M | $5M | $6M | $20M | $26M | $32M | $42M | $43M | $54M | $59M | $20M | |
| PP&E (Net) | · | · | $0 | $0 | $35.0K | $107.0K | $130.0K | $143.0K | $169.0K | $215.0K | $190.0K | $206.0K | $216.0K | $224.0K | $185.0K | $117.0K | |
| PP&E (Gross) | · | · | $0 | $0 | $313.0K | · | · | $331.0K | $349.0K | $386.0K | $338.0K | $398.0K | $387.0K | $368.0K | $300.0K | $446.0K | |
| Accum. Depreciation | · | · | $0 | $0 | $278.0K | · | · | $188.0K | $180.0K | $171.0K | $148.0K | $192.0K | $171.0K | $144.0K | $115.0K | $329.0K | |
| Total Assets | $63M | $9M | $5M | $3M | $2M | $6M | $6M | $7M | $21M | $27M | $33M | $44M | $45M | $55M | $61M | $20M | |
| Accounts Payable | $3M | $3M | $3M | $5M | $6M | $3M | $3M | $2M | $3M | $2M | $2M | $3M | $1M | $3M | $2M | $485.0K | |
| Accrued Liabilities | $2M | $1M | $2M | $1M | $1M | $2M | $3M | $2M | $3M | $5M | $5M | $5M | $4M | $3M | $3M | $3M | |
| Current Liabilities | $17M | $16M | $17M | $27M | $23M | $23M | $21M | $19M | $23M | $22M | $20M | $19M | $10M | $10M | $15M | $13M | |
| Capital Leases | · | · | $0 | $0 | $2.0K | $3.0K | $4.0K | $6.0K | $135.0K | $318.0K | $496.0K | $638.0K | $804.0K | $964.0K | $1M | $10.0K | |
| Total Liabilities | · | · | $17M | $27M | $24M | $26M | $25M | $23M | $32M | $32M | $31M | $32M | $23M | $22M | $20M | $18M | |
| Long-term Debt | · | · | $1M | $7M | $4M | $5M | $5M | $5M | $12M | $12M | $11M | $11M | $12M | $11M | $8M | $10M | |
| Total Debt | $0 | $0 | · | · | · | $5M | $6M | $6M | · | $12M | $12M | $12M | · | $12M | $9M | $10M | |
| Common Stock | $40.0K | $51.0K | $48.0K | $35.0K | $31.0K | $31.0K | $25.0K | $22.0K | $22.0K | $871.0K | $871.0K | $871.0K | $22.0K | $863.0K | $863.0K | $404.0K | |
| Retained Earnings | $-309M | $-304M | $-301M | $-295M | $-291M | $-289M | $-285M | $-281M | $-274M | $-268M | $-261M | $-250M | $-238M | $-226M | $-216M | $-180M | |
| Treasury Stock | · | · | · | · | · | · | · | · | $0 | $2M | $2M | $2M | $2M | $2M | $2M | $2M | |
| Stockholders' Equity | $46M | $-8M | $-12M | $-24M | $-23M | $-20M | $-19M | $-16M | $-11M | $-5M | $2M | $12M | $22M | $33M | $41M | $3M | |
| Liabilities + Equity | $63M | $9M | $5M | $3M | $2M | $6M | $6M | $7M | $21M | $27M | $33M | $44M | $45M | $55M | $61M | $20M | |
| Shares Outstanding | 4,036,398 | 5,072,935 | 4,790,239 | 3,534,250 | 3,143,390 | 2,166,356 | 2,166,356 | 2,166,356 | 2,166,356 | 86,656,221 | 86,656,221 | 86,653,089 | 2,166,248 | 86,252,365 | 86,201,767 | 40,214,874 |
Fluxo de Caixa 11
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q4 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $95.0K | $46.0K | · | · | $340.0K | $418.0K | $610.0K | $597.0K | $641.0K | $714.0K | $744.0K | $922.0K | $2M | $2M | $4M | $1M | |
| Operating Cash Flow | $-5M | $-5M | · | · | $-2M | $-3M | $-2M | $-7M | $-6M | $-7M | $-10M | $-9M | $-10M | $-8M | $-10M | $-8M | |
| CapEx | · | · | · | · | · | $0 | $0 | $0 | $0 | $48.0K | $7.0K | $11.0K | $20.0K | · | · | · | |
| Investing Cash Flow | · | · | · | · | $51.0K | $233.0K | $14.0K | $11.0K | $0 | $-48.0K | $-7.0K | $-11.0K | $-20.0K | $-69.0K | · | · | |
| Debt Issued | $0 | $0 | · | · | · | · | · | · | $0 | · | · | · | $-36.0K | · | · | · | |
| Net Debt Issued | · | $0 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Stock Issued | · | · | · | · | $0 | $2M | $1M | · | $0 | $0 | · | · | $0 | $0 | · | · | |
| Net Stock Activity | · | · | · | · | · | $2M | $1M | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $60M | $7M | · | · | $-2M | $4M | $1M | $-8M | $312.0K | $2M | $0 | $7M | $-160.0K | $3M | $46M | $1M | |
| Net Change in Cash | $56M | $2M | · | · | $-4M | $453.0K | $-624.0K | $-14M | $-5M | $-5M | $-10M | $-3M | $-10M | $-4M | $39M | $-6M | |
| Free Cash Flow | · | · | · | · | · | · | · | $-7M | · | · | · | $-10M | · | · | · | · |
Lucratividade 2
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q4 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -13.0% | -47.8% | · | · | · | -21.8% | -22.3% | -24.5% | · | -18.2% | -22.7% | -36.3% | · | -22.4% | -71.7% | -25.8% | |
| ROE | -32.4% | 31.4% | · | · | · | 28.7% | 51.7% | 270.5% | · | -53.6% | -50.0% | -161.0% | · | -41.1% | -118.3% | -59.9% |
Liquidez e Solvência 4
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q4 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.7 | 0.5 | · | · | · | 0.2 | 0.3 | 0.3 | · | 1.2 | 1.6 | 2.2 | · | 5.6 | 3.9 | 1.6 | |
| Quick Ratio | 3.7 | 0.4 | · | · | · | 0.2 | 0.2 | 0.3 | · | 1.1 | 1.5 | 2.1 | · | 5.5 | 3.7 | 1.4 | |
| Debt / Equity | 0.0 | 0.0 | · | · | · | -0.3 | -0.3 | -0.3 | · | -2.5 | 6.8 | 1.0 | · | 0.4 | 0.2 | 3.8 | |
| LT Debt / Equity | · | · | · | · | · | -0.1 | -0.2 | -0.2 | · | -2.0 | 6.1 | 1.0 | · | 0.4 | 0.1 | 1.8 |
Avaliação (TTM) 6
| Métrica | Tendência | Q2 2026 | Q1 2026 | Q4 2025 | Q4 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | · | · | · | · | · | $-22M | $-29M | $-36M | · | $-40M | $-68M | $-66M | · | $-61M | $-59M | $-37M | |
| Market Cap | $56M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Enterprise Value | $-6M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/B | 1.2 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| P / Tangible Book | 1.2 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| EV / EBITDA | 1.3 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
Demonstrações Financeiras Demonstração de resultados, balanço patrimonial, fluxo de caixa — anual, últimos 5 anos
Demonstração de Resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Receita | $0 | $6M | $0 | — | — |
| Lucro líquido | $-6M | $-3M | $-17M | $-36M | $-67M |
| EPS Diluído | $-0.49 | $-0.84 | $-6.63 | $-16.65 | $-38.15 |
Balanço Patrimonial
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Dívida / Patrimônio Líquido | -0.1 | — | — | -1.2 | 0.5 |
| Índice de liquidez corrente | 0.3 | — | — | 0.9 | 4.4 |
| Índice de Liquidez Seca | 0.3 | — | — | 0.8 | 4.2 |
Fluxo de Caixa
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Fluxo de caixa livre | — | — | — | $-32M | $-35M |
Minhas Métricas Sua lista pessoal — linhas selecionadas de Fundamentos Completos
📊
Escolha as métricas que importam para você — clique no ➕ ao lado de qualquer linha em Fundamentos Completos acima.
Sua seleção é salva e acompanha você em todos os tickers.
Executivos da empresa 46 insiders · 16 diretores · 23 conselheiros
| Investidor com informação privilegiada | Função | Última atividade | Ações detidas | Compras 12m | Vendas 12m | Líquido 12m |
|---|---|---|---|---|---|---|
| Sumit Aggarwal | President and CEO | 10 de Junho de 2026 A | 1.672.756 | 0 | 0 | $0 |
| Gregory C. Williams | CHIEF EXECUTIVE OFFICER | 25 de Fevereiro de 2021 M | 44.629 | 0 | 0 | $0 |
| Ron Martell | Chief Executive Officer | 18 de Novembro de 2014 A | — | 0 | 0 | $0 |
| Daniel E. Geffken | INTERIM CFO | 29 de Novembro de 2021 P | 50.000 | 0 | 0 | $0 |
| Joel Brooks | Chief Financial Officer | 18 de Novembro de 2014 A | 90.875 | 0 | 0 | $0 |
| Leslie J Browne | President | 18 de Novembro de 2014 A | 1.290 | 0 | 0 | $0 |
| Neil S. Belloff | COO, GENERAL COUNSEL &CORP SEC | 30 de Julho de 2021 M | 32.699 | 0 | 0 | $0 |
| Vijay Modur | HEAD OF R&D | 25 de Janeiro de 2023 A | 154.953 | 0 | 0 | $0 |
| Stephen G. Macdonald | VP FINANCE & ACCTG, TREASURER | 12 de Fevereiro de 2021 A | — | 0 | 0 | $0 |
| Pedro Huertas | Chief Medical Officer | 16 de Maio de 2018 A | 137.725 | 0 | 0 | $0 |
| Miguel De Los Rios | VP - Research | 18 de Novembro de 2014 A | — | 0 | 0 | $0 |
| James Joseph Graziano | Chief Technology Officer | 18 de Novembro de 2014 A | 104.386 | 0 | 0 | $0 |
| Vaughn Smider | Chief Scientific Officer | 18 de Novembro de 2014 A | 1.058.970 | 0 | 0 | $0 |
| Richard S Dondero | VP - Preclinical Research | 18 de Novembro de 2014 A | — | 0 | 0 | $0 |
| John Thompson PHD | Scientific Founder | 18 de Novembro de 2014 A | — | 0 | 0 | $0 |
| Sascha P Fedyszyn | VP - Corporate Dev. | 19 de Novembro de 2009 D | 153.460 | 0 | 0 | $0 |
| Alan Edmund Walts | Conselheiro | 8 de Junho de 2026 A | 15.567 | 0 | 0 | $0 |
| Stephen W Webster | Conselheiro | 8 de Junho de 2026 A | — | 0 | 0 | $0 |
| Nina S Kjellson | Conselheiro | 8 de Junho de 2026 A | — | 0 | 0 | $0 |
| Steven D Rubin | Conselheiro | 8 de Junho de 2026 A | 14.625 | 0 | 0 | $0 |
| Lindsay Androski | Conselheiro | 24 de Janeiro de 2025 M | 15.750 | 0 | 0 | $0 |
| Tomer Kariv | Conselheiro | 30 de Janeiro de 2023 A | 616.592 | 0 | 0 | $0 |
| Jasbir Seehra | Conselheiro | 15 de Junho de 2022 A | — | 0 | 0 | $0 |
| Zafrira Avnur | Conselheiro | 15 de Junho de 2022 A | 2.263 | 0 | 0 | $0 |
| Gadi Veinrib | Conselheiro | 15 de Junho de 2022 A | — | 0 | 0 | $0 |
| Ran Nussbaum | Conselheiro | 15 de Junho de 2022 A | 616.592 | 0 | 0 | $0 |
| Rajesh R Parekh | Conselheiro | 15 de Junho de 2022 A | 4.827.129 | 0 | 0 | $0 |
| Martijn Kleijwegt | Conselheiro | 20 de Maio de 2020 A | 2.953.673 | 0 | 0 | $0 |
| Silvia Noiman | Conselheiro | 20 de Maio de 2020 A | 490.789 | 0 | 0 | $0 |
| Harlan Waksal | Conselheiro | 19 de Novembro de 2015 A | 2.805.750 | 0 | 0 | $0 |
| Christopher Forbes | Conselheiro | 18 de Novembro de 2014 A | 12.757.318 | 0 | 0 | $0 |
| Warren John Isabelle | Conselheiro | 16 de Maio de 2014 A | 6.038 | 0 | 0 | $0 |
| Jack Van Hulst | Conselheiro | 16 de Maio de 2014 A | 40.068 | 0 | 0 | $0 |
| Thomas C Quick | Conselheiro | 16 de Maio de 2014 A | 13.149 | 0 | 0 | $0 |
| Ruedi Stalder | Conselheiro | 16 de Maio de 2014 A | 1.053.938 | 0 | 0 | $0 |
| Domicilium Real Estate Fund III LP | Detentor de 10% | 10 de Junho de 2026 J | 361.578 | 0 | 0 | $0 |
| Coastlands Capital LP | Detentor de 10% | 27 de Maio de 2026 J | 0 | 0 | 0 | $0 |
| Gilad Shabtai | Detentor de 10% | 30 de Abril de 2018 P | 3.351.770 | 0 | 0 | $0 |
| Paul Edward Klaver | Detentor de 10% | 22 de Março de 2012 G | 10.146.527 | 0 | 0 | $0 |
| Gregory L Weaver | — | 15 de Março de 2020 M | 10.431 | 0 | 0 | $0 |
| Robert Ward | — | 29 de Fevereiro de 2020 M | 244.267 | 0 | 0 | $0 |
| David P. Snow | — | 30 de Janeiro de 2020 M | 4.205 | 0 | 0 | $0 |
| John N Braca | — | 19 de Dezembro de 2017 A | 137.964 | 0 | 0 | $0 |
| David Rector | — | 19 de Dezembro de 2017 A | 352.785 | 0 | 0 | $0 |
| Phillip Frost, M.D. | — | 19 de Dezembro de 2017 A | — | 0 | 0 | $0 |
| Bruce C Galton | — | 1 de Dezembro de 2009 S | 98.450 | 0 | 0 | $0 |
Executivos de declarações SEC Formulário 3/4/5; líquido = apenas P/V de mercado aberto
Ativistas e proprietários de 5%+ 21 participações
Investidores que apresentaram o Schedule 13D da SEC — propriedade benéfica acima de 5% com a intenção de influenciar o emissor (participações ativistas, campanhas no conselho, M&A). Cada linha mostra o estado mais recente conhecido da posição desse declarante.
| Declarante | Declarado | Participação | Status | Propósito | Declaração |
|---|---|---|---|---|---|
| Advent Life Sciences LLP, Advent Life Sciences Fund II LP, Rajesh Parekh, Shahzad Malik, Kaasim Mahmood, Dominic Schmidt ×2 declarações | 20 de Agosto de 2024 | — | Emenda | — | SEC |
| LSP V Coöperatieve U.A, LSP V Management B.V. ×2 declarações | 3 de Fevereiro de 2022 | — | Emenda | — | SEC |
| Pontifax Management III G.P. (2011) Ltd., Pontifax Management Fund III L.P., Pontifax (Cayman) III, L.P., Pontifax (Israel) III, L.P., Pontifax Management 4 G.P. (2015) Ltd., Pontifax IV GP L.P., Pontifax (Cayman) IV L.P., Pontifax (Israel) IV L.P., Pontifax (China) IV L.P., Pontifax Late Stage GP Ltd., Pontifax Late Stage Fund L.P. ×4 declarações | 21 de Maio de 2021 | — | Emenda | — | SEC |
| LSP V Coöperatieve U.A., LSP V Management B.V. | 29 de Dezembro de 2017 | — | Declaração inicial | — | SEC |
| Dr. Phillip Frost, Frost Gamma Investments Trust ×6 declarações | 27 de Dezembro de 2017 | — | Emenda | Campanha no conselho | SEC |
| Vaughn Smider, M.D., Ph.D. ×2 declarações | 19 de Junho de 2014 | — | Emenda | — | SEC |
| Christopher Forbes ×3 declarações | 19 de Janeiro de 2012 | — | Emenda | Investimento passivo | SEC |
| John E. Thompson, Ph.D. | 14 de Fevereiro de 2005 | — | Emenda | — | SEC |
| Pessoa de relato não divulgada | 18 de Fevereiro de 2003 | — | Emenda | — | SEC |
| Pessoa de relato não divulgada | 14 de Fevereiro de 2003 | — | Emenda | — | SEC |
| Pessoa de relato não divulgada | 14 de Fevereiro de 2003 | — | Emenda | — | SEC |
| Pessoa de relato não divulgada | 12 de Fevereiro de 2003 | — | Emenda | Investimento passivo | SEC |
| Pessoa de relato não divulgada | 28 de Março de 2002 | — | Emenda | — | SEC |
| Pessoa de relato não divulgada | 13 de Fevereiro de 2002 | — | Emenda | — | SEC |
| Pessoa de relato não divulgada | 13 de Fevereiro de 2002 | — | Emenda | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Participação em ETFs Detido por 2 ETFs
O peso reflete apenas participações diretas em ações (N-PORT); fundos alavancados ou baseados em derivativos podem deter exposição adicional a swaps não mostrada.